A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction.

Trial Profile

A Multi-center, Prospective, Randomized, Open-label Study With Blinded Outcome Evaluation to Evaluate the Effects of Systolic Blood Pressure Lowering to Different Targets (Less Than 130 mmHg vs. Less Than 140 mmHg) on Diastolic Function Using Valsartan + Amlodipine in Patients With Hypertension and Diastolic Dysfunction.

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Apr 2012

At a glance

  • Drugs Valsartan (Primary) ; Amlodipine
  • Indications Essential hypertension; Hypertension; Left ventricular dysfunction
  • Focus Therapeutic Use
  • Acronyms EXCEED
  • Sponsors Novartis
  • Most Recent Events

    • 09 Mar 2011 Actual end date (Jan 2008) added as reported by ClinicalTrials.gov.
    • 01 Feb 2010 Results published in Hypertension.
    • 22 Dec 2008 Planned number of patients addede (193) as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top